Ariana Pelosci

Patients with non–small cell lung cancer treated with targeted therapies experienced an overall survival benefit.

Compared with placebo, ruxolitinib cream significantly improved body surface area in patients with cutaneous graft-vs-host disease in a phase 2 trial.

Treatment-emergent symptoms were easily resolved after treatment with olaparib for BRCA1/2 high-risk HER2-negative breast cancer, as shown in a patient reported outcome analysis of the phase 3 OlympiA trial.

Nivolumab plus chemotherapy enhanced overall survival and progression-free survival in patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.

Findings presented at the 2023 San Antonio Breast Cancer Symposium described some possible avenues for artificial intelligence to be useful in breast cancer care.

In a single-center retrospective analysis, the median progression-free survival among patients with multiple myeloma treated with teclistamab was 4.7 months.

Capivasertib plus fulvestrant improved progression-free survival in patients who have hormone-receptor–positive/HER2-negative advanced breast cancer.

Daratumumab plus lenalidomide and dexamethasone bested standard therapy in producing rapid, deep, and durable responses across subgroups of patients with newly diagnosed multiple myeloma.